An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria (ePHex-OLE)

O

OxThera

Status and phase

Terminated
Phase 3

Conditions

Hyperoxaluria, Primary

Treatments

Biological: Oxabact OC5 - Oxalobacter formigenes Strain HC-1

Study type

Interventional

Funder types

Industry

Identifiers

NCT03938272
OC5-OL-02

Details and patient eligibility

About

Open label extension study of Oxabact OC5 in patients with primary hyperoxaluria

Full description

OC5-OL-02 (ePHex-OLE) is a 2 year, open-label, extension study to evaluate the long-term efficacy and safety of Oxabact OC5 for patients with primary hyperoxaluria who completed treatment in the parent double-blind, placebo-controlled study OC5-DB-02 (ePHex).

Enrollment

22 patients

Sex

All

Ages

3+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent (as applicable for the age of the subject).
  • Participation in and completion of study OC5-DB-02.
  • Subjects who had received vitamin B6 during OC5-DB-02 study should maintain a stable dose. Subjects not receiving vitamin B6 during OC5-DB-02 must be willing to refrain from initiating pyridoxine during study participation.

Exclusion criteria

  • Inability to swallow size 4 capsules.
  • Use of antibiotics to which O. formigenes is sensitive.
  • Current treatment with a separate ascorbic acid preparation.
  • Pregnant or lactating women (or women who are planning to become pregnant).
  • Women of childbearing potential who are not using adequate contraceptive precautions.
  • Presence of a medical condition that the Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures or any condition that is likely to interfere with the study drug mechanism of action (such as abnormal GI function).
  • Participation in any interventional study of another investigational product, biologic, device, or other agent or not willing to forego other forms of investigational treatment during this study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

22 participants in 1 patient group

Oxabact OC5 capsules
Experimental group
Description:
Oxabact OC5 - Oxalobacter formigenes Strain HC-1
Treatment:
Biological: Oxabact OC5 - Oxalobacter formigenes Strain HC-1

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems